Consumer Reports questions self-ordered hormone packages. Learn why clinical context matters and what its advice means for testosterone testing.
On October 12, 2026, Consumer Reports published Hallie Levine’s “Blood Tests You Need (and Don’t)” with advice to skip broad self-ordered men’s hormone packages in favor of discussing appropriate testing with a clinician.
This article is for informational purposes and is not medical advice. Decisions about testing or treatment belong with a qualified clinician.
According to Consumer Reports, a men’s self-ordered hormone package might include testosterone and sex-hormone-binding globulin (SHBG). The list may also include albumin, estradiol and prolactin.
Consumer Reports puts the cost of these packages at $150 to $300. Its recommendation to skip them reflects the views of experts interviewed for the article. The report contrasts buying that package with obtaining testosterone testing through a doctor’s office.
That comparison gives readers a more useful starting point than a list of included tests. What health concern would the testing address? Who would explain the results? Those questions connect the purchase decision to the clinical purpose that Consumer Reports asks readers to consider.
The publication also discusses broader direct-to-consumer products and whole-body panels. Men’s hormone packages are one category within that wider discussion. For this article, the relevant issue is the value of buying a hormone package rather than the size or price of a different testing product.
For context, Consumer Reports says some of the whole-body kits it discusses measure more than 80 biomarkers and cost about $300 to almost $900. Those figures apply to the broader kits rather than the men’s hormone packages. Keeping the categories separate matters when comparing what the article says about price and scope.
Consumer Reports quotes Cory Fisher, DO, a Cleveland Clinic family medicine physician, about when his practice orders testosterone tests. He describes testing men who have symptoms such as erectile dysfunction and a dramatic decrease in sex drive.
His account places a reason for testing before the test order. For readers researching sexual symptoms, the immediate question is how to discuss those concerns with a clinician. It is not which package contains the longest list of hormone-related measurements.
Consumer Reports says testosterone testing is available through a doctor’s office and is usually covered by insurance. That is an important part of its value comparison: a paid package is being weighed against another route to testing, not against having no access to testing at all.
For someone sorting through unfamiliar lab terms, understanding the vocabulary is a separate task from deciding what to order. Background on total and free testosterone terminology can help organize questions without turning a package description into a personal testing plan.
The report also describes a concern raised by Sheldon Campbell of Yale-New Haven Health and the College of American Pathologists. Consumers may receive many biomarker results without knowing how to interpret them. Consumer Reports presents Campbell’s recommendation to discuss such products with a primary-care provider before buying them.
This is a distinction between receiving information and understanding its relevance. A report can show what a laboratory measured. The next question is what those results mean in relation to the concern that led someone to seek testing.
Consumer Reports advises discussing testing with a doctor and sharing results with one. For tests that are not FDA-approved, it also advises checking whether the laboratory is accredited by CLIA or the College of American Pathologists. These are separate considerations: the laboratory’s accreditation and the clinical reason for choosing the tests.
The practical value of that distinction is straightforward. Someone considering a package can ask about both the laboratory and the purpose of the measurements. A discussion focused only on the number of included biomarkers leaves the second question unanswered.
Consumer Reports published consumer advice based on expert interviews. It did not report a head-to-head trial comparing broad self-ordered hormone packages with clinician-directed testing. The article therefore offers a purchasing recommendation rather than evidence that one testing route produces better health outcomes or that every package causes harm.
Its scope is the package purchase. The recommendation should not be read as a ruling that SHBG or every other included marker is clinically useless. The article does not evaluate whether albumin, estradiol or prolactin is appropriate for each patient or explain when a clinician would add those tests.
Fisher’s symptom examples are a description of his practice rather than a complete diagnostic guideline. They are not an exhaustive symptom list. Symptoms alone are not presented as establishing low testosterone.
The report also supplies no testosterone threshold or required number of blood draws. It does not set out test timing, explain how to interpret conflicting results or provide a treatment protocol. Those details should not be filled in by treating its consumer recommendation as a medical guideline.
Finally, its statement about insurance is qualified: clinician-ordered testosterone testing is usually covered. That wording should not be turned into a promise that a particular person’s test will be paid for.
For men concerned about possible low testosterone, the report supports starting with the reason for testing. Consumer Reports advises discussing testing with a doctor. A clinical conversation can address symptoms and health history before deciding whether a self-ordered package is worth purchasing.
A useful discussion can stay close to the questions raised by the report:
These questions do not require readers to know which additional marker belongs in their own workup. They make the decision more specific: what is being measured, why it is being measured and how the result will be discussed. Testostra’s overview of preparing for a first testosterone evaluation provides a place to organize that conversation.
For anyone who already has self-ordered results, Consumer Reports recommends sharing them with a doctor. The relevant next discussion is about interpreting the report in clinical context. The purchase has already happened, but the results can still be brought into a clinician-directed evaluation.
There is no need to turn that discussion into a judgment about the decision to buy the package. The report’s useful message is about what happens before and after measurement: choosing tests for a reason and having someone qualified explain their relevance.
The bottom line is that this advice should inform testing discussions and purchasing decisions rather than immediately change medical practice. It does not justify a new diagnostic rule or a change in hormone treatment. Personal decisions about further testing or treatment remain matters for qualified care.
Buying a hormone package can leave the main question unanswered: how its results relate to a health concern. Testostra explains total testosterone, free testosterone and SHBG within evidence-led coverage of male hormonal health, helping readers understand the vocabulary and clinical context without treating a collection of numbers as personal medical advice.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra